Download Manual of Endocrinology and Metabolism PDF

TitleManual of Endocrinology and Metabolism
File Size16.5 MB
Total Pages2040
Table of Contents
                            Title Page
A Brief Autobiography
Section 1 Basic Science of Clinical Endocrinology
	1 Clinical Molecular Endocrinology Laboratory Testing
	2 Hormone-Resistant States
	3 Genetics of Endocrinology
	4 The Growth Plate
Section 2 Hypothalamic-Pituitary Dysfunction
	5 Anterior Pituitary Diseases
	6 Hypopituitarism after Traumatic Brain Injury
	7 Prolactin
	8 Nipple Discharge/Galactorrhea
	9 Acromegaly/Gigantism
	10 Clinical Disorders of Vasopressin
	11 Preoperative, Intraoperative, and Postoperative Management Following Pituitary Surgery
	12 Growth Hormone in Adults
	13 Pituitary Disorders and Tall Stature in Children
	14 Short Stature and Growth Hormone Therapy
	15 Laron Syndrome
	16 Prader–Willi Syndrome
Section 3 Adrenal Disorders
	17 The Adrenal Cortex and Mineralocorticoid Hypertension
	18 Pheochromocytoma and Paraganglioma
	19 Hormonal Hypertension
	20 Use of Salivary Cortisol Assay to Screen for Cushing Syndrome/Disease
	21 Adrenal Hormones during Acute and Chronic Illness: Evaluation and Treatment
	22 Congenital Adrenal Hyperplasia
	23 Adrenal Steroid Excess in Childhood
	24 Adrenal Insufficiency in Childhood
Section 4 Disorders of the Reproductive System
	25 Female Reproductive Endocrinology in Adults
	26 Polycystic Ovary Syndrome
	27 Male Reproductive Disorders in Adults
	28 Disorders of Sexual Development in the Pediatric and Adolescent Male
	29 Early, Precocious, and Delayed Female Pubertal Development
	30 Ambiguous Genitalia
Section 5 Mineral Disorders
	31 Disorders of Calciotropic Hormones in Adults
	32 Hypercalcemic Crisis
	33 Metabolic Bone Disease
	34 Parathyroid Hormone-Related Protein
	35 Common Bone and Mineral Disorders of Childhood
Section 6 Thyroid Disorders
	36 Evaluation of Thyroid Function
	37 Thyroiditis
	38 Hypothyroidism and Hyperthyroidism
	39 Thyroid Tumors in Adults
	40 Newborn Thyroid Disorders and Screening
	41 Thyroid Nodules and Thyroid Cancer in Children and Adolescents
	42 Thyroid Disorders in Children and Adolescents
Section 7 Metabolic Disorders
	43 Obesity
	44 Disorders of Lipid Metabolism
	45 Hypoglycemia in Adults
	46 Hypoglycemia in Infants and Children
	47 Congenital Hyperinsulinism
Section 8 Inborn Errors of Metabolism
	48 Introduction to Inborn Errors of Metabolism
	49 Glycogen Storage Diseases
	50 Hypokalemic Paralysis
Section 9 Diabetes Mellitus
	51 Etiology, Pathogenesis, and Therapy of Type 1 Diabetes Mellitus
	52 Diagnosis and Management of Type 1 Diabetes Mellitus in Children, ­Adolescents and Young Adults
	53 Hypoglycemia-Associated Autonomic Failure (HAAF) in Diabetes Mellitus
	54 Diabetic Ketoacidosis
	55 Type 2 Diabetes Mellitus
	56 Glucose Control in Glucocorticoid-Induced Hyperglycemia
	57 Bariatric Surgery in Adults with Type 2 Diabetes
	58 Diabetes Mellitus and the Geriatric Patient
	59 Diabetes Mellitus Type 2, Obesity, Dyslipidemia, and the Metabolic Syndrome in Children
	60 Type 1.5 Diabetes: Overlay between Type 1 and Type 2 Diabetes
	61 C-Peptide
	62 Cystic Fibrosis Related Diabetes
	63 Diabetes in Pregnancy
	64 Management of Diabetes Mellitus in the Perioperative Period
	65 Diabetes Mellitus: Recent Developments and Clinical Implications
	66 Artificial Pancreas
	67 Glycated Proteins in the Diagnosis and Management of Type I and Type II Diabetes Mellitus
	68 Inhaled Insulin
	69 The Application of Stem Cells in Diabetes Mellitus
Section 10 Sex Hormone Treatments
	70 The Care of Gender-nonconforming and Transgender Youth
	71 Hormone Therapy in Transgender Adults
	72 How to Manage Men with Low Testosterone
	73 The Use of Hormones in Female Sexual Dysfunction
	74 Menopausal Hormone Therapy
Section 11 Special Topics in Clinical Endocrinology
	75 Endocrine Diseases in Pregnancy
	76 Fetal Endocrinology and Neonatal Emergencies
	77 Hormones and Aging
	78 Neuroendocrine (APUD) Syndromes
	79 Multiple Endocrine Neoplasia Syndromes
	80 Radiology, Nuclear Medicine, and Endocrinology
	81 Surgery for Endocrine Disorders
	82 Surgical Management of Pediatric Endocrine Diseases
	83 Biomarkers Used in the Screening, Diagnosis, Management, and Surveillance of Endocrine Cancers
	84 Autoimmune Endocrine Syndromes
	85 Management of Some Hormone-Dependent Cancers with Analogs of ­Hypothalamic Hormones
	86 Endocrine-Disrupting Chemicals
	87 Flushing and Sweating
	88 Intranasal Hormones
	89 The Female Athlete
Appendix A Protocols for Stimulation and Suppression Tests Commonly Used in Clinical Endocrinology
Document Text Contents
Page 2

Fifth Edition

Page 1020






evaluate for a thyroid nodule as the cause of, or associated with,
hyperthyroidism. A RAIU and scan may be used to diagnose
patients with clinical hyperthyroidism but nonelevated TSI. If
the TSI is elevated, there is no need to perform a diagnostic
RAIU and scan.

Marine–Lehnhart syndrome describes a patient with an
autonomously functioning nodule or toxic multinodular
goiter in the setting of Graves disease.
Patients with “silent” or painless thyroiditis are
asymptomatic with mild or subclinical hyperthyroidism and
low uptake at 24 hours. The expectant course for these
patients is a period of subclinical hypothyroidism followed
by euthyroidism.
Rarely, a patient is so hyperthyroid that an early uptake at 2
to 4 hours is very high, but by 24 hours, the uptake is
normal. These patients with high turnover of iodine may
experience a rapid-response to antithyroid medication as
well as a rapid rate of relapse. Radioiodine ablation may
also be less effective but may be made more effective with
coadministration of lithium.
The ultrasensitive TSH will be normal or low unless the
hyperthyroidism is caused by a rare TSH-producing tumor.
A TSH-secreting adenoma is typically associated with an
elevated T3 and T4 and nonsuppressed TSH. An elevated α-
subunit and/or MRI showing a pituitary tumor is diagnostic.
Thyroglobulin (Tg) is elevated in all forms of thyroiditis
but is not needed for diagnosis or management of
autoimmune thyroid disease. A suppressed Tg in the setting
of hyperthyroidism with nonelevated TSI or TRAb, no
nodule on thyroid US, and no evidence of a genetic disorder
associated with hyperthyroidism, should raise suspicion for
the diagnosis of “factitious” hyperthyroidism
secondary to ingestion of excess T3 and/or T4.

p. 573p. 574
TABLE 42-7 Clinical Features of Graves Disease in Childhood

Page 1021

Organ Signs Symptoms

Page 2039

classification of overweight and obesity by, 589t
measurement of, 596

Waning insulin availability, 726
Wasting syndrome, 138
Water deprivation test, 154, 155, 1074–1075

for diabetes insipidus
interpretation, 108–109
method, 108
precautions, 108

Water intake, 109
Water intoxication, 157
Water permeability, vasopressin on, effect of, 103
Waterhouse–Friderichsen syndrome, 281
Waxy maize cornstarch, extended release, 681
WDHA syndrome. See VIPoma
Weaver syndrome, 159
Webb–Dattani syndrome, 144

p. 1165p. 1166
Wechsler Adult Intelligence Scale 3, 71

gain, 961
drug-induced, 590
menstrual function and, 1061

inhaled technosphere insulin effect on, 878, 879
loading, on bone mass, 437
loss, 713
bariatric surgery in type 2 diabetes, 772
and diabetes management, 792–793
online diets, 595t
treatable causes of, 966–967, 967t

Welchol (colesevelam), 614t, 617, 812t
Wermer syndrome, 152. See Multiple endocrine neoplasia type 1 (MEN1)
Wet flushing, 1044, 1045t, 1046
WFS1 (4p16), 153
Whipple’s triad, 632, 641
Whole-exome sequencing, 5
Whole-genome sequencing, 5
Williams syndrome, 30, 32, 463
Wilson disease, 408, 671
Wingless-related integration sites (WNTs), 44
Wingless-type MMTV integration site family members (WNTs), 50
Wisconsin Card Sorting Test, 71
Wisconsin Eye Study, 778
WNT4, 379
Wolff–Chaikoff effect, 497, 536, 577
Wolffian ducts, 289
Wolffian structures, 379–380
Wolf–Hirschhorn syndrome, 32
Wolfram syndrome, 153
Wolman disease, 281
Women’s Health Initiative Study, 917, 1036

Page 2040

World Anti-Doping Agency, 1061
World Health Organization (WHO), 963

criteria for severity of bone loss, 426
definition of osteoporosis, 476

World Professional Association for Transgender Health (WPATH), 893, 894
World Professional Association of Transgender Health Standards of Care, 889

X inactivation, 39
X-linked disorders, 3
X-linked hypophosphatemia (XLH), 439, 473
X-linked hypophosphatemic rickets, 167, 391
Xanthelasmas, 606
XD endocrine disorders, 37–38
Xenical (orlistat), 497t, 499, 598, 599t, 804
XR endocrine disorders, 37
Xultophy (iDegLira), 855, 861

Y-bearing cell line, in dysgenetic gonads, 32
90Yttrium, 1036

Z-score, 426
Zemplar (paricalcitol), 441
Zetia (ezetimibe), 615t, 617, 812t
Zinc deficiency, 779
Zinc transporter 8 (ZnT8), 1027
Zocor (simvastatin), 612t, 614t, 812t, 813
Zofran (ondansetron), 724
Zoladex (Goserelin), 1033, 1034, 1035
Zoledronate, 466, 485
Zoledronic acid (Reclast), 397, 404–405, 422, 430–431, 434, 435, 443, 449, 965, 1033
Zollinger–Ellison syndrome, 971, 977, 982. See also Gastrin, producing tumor
Zona fasciculata, of adrenal gland, 270
Zona glomerulosa, of adrenal gland, 270
Zona reticularis, of adrenal gland, 270
Zoptarelin, 1035

p. 1166

Similer Documents